 TopNews New Zealand | Novartis Phase III study in acute heart failure Pharmacy Europe Phase III study results show that investigational RLX030 (serelaxin) reduced all-cause mortality in patients with acute heart failure (AHF).[1] The six-month RELAX-AHF study shows that RLX030 reduces the number of deaths in patients with this disease, ... Heart Failure Drug Promising in Phase III Trial Novartis drug cuts deaths in heart failure patients Novartis's drug reduces heart failure deaths: study |
